Lupin Acquires US rights For Antara
For a cash consideration of $38.61m
Lupin has acquired US rights for Antara (Fenofibrate capsules 43mg, and 130mg) for $38.61m from Oscient Pharmaceuticals.
Lupin had filed an ANDA for fenofibrate capsules 43mg and 130mg. The company sold the ANDA to Dr Reddy's Laboratories and also settled the pending litigation relating to the product.
Vinita Gupta, group president and CEO of Lupin, said: "We are very excited with our second NDA acquisition within a span of four months. The Antara acquisition demonstrates Lupin's success in, and commitment to building its brand franchise and equity in the US. It underlines Lupin's differentiated strategy for the US market. Antara is a step forward that will help us strengthen and grow our brand business. Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our topline and bottomline in the coming quarters and years."
Antara is aimed at adjunct treatment of hypercholesterolemia and hyper-triglyceridemia in combination with diet. Reportedly, the Antara acquisition enables Lupin to enter the primary care market with a three products portfolio.
Related Insight
Suppliers Directory
Synergy Outsourcing - Outsourcing and Insourcing Solutions
Synergy outsourcing is a functional service provider giving the outsourcing industry a unique dual channel approach to outsourcing.
Drug Research > Drug Discovery & Development > Suppliers
AR2i - Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware
AR2i is a leading research laboratory dedicated to analytical methods and quality control of pharmaceuticals, parapharmaceuticals and some cosmetic products, on behalf of laboratories and consulting companies.
Drug Research > Drug Discovery & Development > Suppliers
INC Research - CRO for Drug and Device Development
INC Research is a therapeutically focused global contract research organisation (CRO) with unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity.
Drug Research > Drug Discovery & Development > Suppliers
Turku Region - A Bright Future in a Great Location
Turku Region not only boasts a solid track record in the development of pharmaceutical products, but also has a long history of academic achievement.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
IT Platform Toolkit
Published by ChemAxon
Drug Research > Drug Discovery & Development > White Papers
SynBiosys™ Drug Delivery Systems
Published by InnoCore Technologies BV
Drug Research > Drug Discovery & Development > White Papers
Protecting Sensitive Information in Life Sciences Organisations
Published by Brainloop
Drug Research > Drug Discovery & Development > White Papers
Management and Analysis of Biomarker Data
Published by Exploristics
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.